A targeted BRCA1/2 gene panel, utilizing the single-tube SLIMamp workflow for fast library prep and turnaround time.
The Pillar oncoReveal BRCA1 & BRCA2 + CNV Panel targets BRCA1/2 mutations and copy number variations. The assay uses proprietary Stem Loop Inhibition-Mediated amplification (SLIMamp) technology, a tiled amplicon-based library prep chemistry for efficient single-tube target enrichment.
| Content specifications | Covers full coding gene sequence, plus flanking intronic regions (10bp) |
|---|---|
| Instruments | MiSeq System, NextSeq 550 System, MiSeqDx in Research Mode, NextSeq 550Dx in Research Mode, MiSeq i100 System, MiSeq i100 Plus System |
| Method | Targeted DNA sequencing, Amplicon sequencing |
| Nucleic acid type | DNA |
| Specialized sample types | Blood, Low-input samples, FFPE tissue |
| Species category | Human |
| Technology | Sequencing |
| Variant class | Somatic variants, Germline variants, Single nucleotide variants (SNVs), Insertions-deletions (indels), Copy number variants (CNVs) |
Pillar oncoReveal panels require the use of a Pillar index kit.
Pillar oncoReveal panels require the use of a Pillar index kit. Pick your preferred number of reactions.
Pillar oncoReveal BRCA1 & BRCA2 + CNV Panel
| Pillar oncoReveal BRCA1 & BRCA2 + CNV Panel | AmpliSeq for Illumina BRCA Panel | |
|---|---|---|
| Content specifications | Covers full coding gene sequence, plus flanking intronic regions (10bp) | Exonic regions and the flanking intronic sequences of the BRCA1 and BRCA2 |
| Instruments | MiSeq System, NextSeq 550 System, MiSeqDx in Research Mode, NextSeq 550Dx in Research Mode, MiSeq i100 System, MiSeq i100 Plus System | MiSeq System, iSeq 100 System, MiSeqDx in Research Mode, MiniSeq System |
| Method | Targeted DNA sequencing, Amplicon sequencing | Targeted DNA sequencing, Amplicon sequencing |
| Nucleic acid type | DNA | DNA |
| Specialized sample types | Blood, Low-input samples, FFPE tissue | Blood, FFPE tissue |
| Species category | Human | Human |
| Technology | Sequencing | Sequencing |
| Variant class | Somatic variants, Germline variants, Single nucleotide variants (SNVs), Insertions-deletions (indels), Copy number variants (CNVs) | Single nucleotide polymorphisms (SNPs), Somatic variants, Germline variants, Insertions-deletions (indels) |
Pillar oncoReveal BRCA1 & BRCA2 Plus CNV Panel specifications for the detection of DNA variants from BRCA 1 and BRCA2.
Pillar® oncoReveal™ BRCA1 & BRCA2 + CNV Panel (24 reactions)
HDA-BR-1003-24
Pillar® oncoReveal™ BRCA1 & BRCA2 + CNV Panel (24 reactions)
Indices PI501-8, PI701-4 (32 combinations, 96 reactions)
IDX-PI-1001-96
Indices PI501-8, PI701-4 (32 combinations, 96 reactions)
List Price:
Discounts:
Kit D, indices PI501-8, PI701-12
IDX-PI-1004-192
Kit D, indices PI501-8, PI701-12
List Price:
Discounts:
Showing of
Product
Qty
Unit price
Product
Catalog ID
Quantity
Unit price
Simplified operations, advanced chemistry, and onboard informatics provide an easy-to-use, fast, and flexible instrument supporting a broad range of applications.
Operationalize informatics and drive scientific insights with Illumina Connected Analytics. Contact us for information on pricing, subscriptions, and more.
Reagents for the MiSeq i100 Series feature easy-to-use cartridges and multiple flow cell configurations for flexible sequencing options.
Targeted panel targeting 83 RNA fusions from FFPE tissue across multiple solid tumor types.
A robust assay targeting key mutations in MPL, JAK2, and CALR genes, utilizing single-tube SLIMamp workflow for fast library prep and turnaround time.
A pan-cancer panel with combined DNA/RNA content, utilizing the single-tube SLIMamp workflow for fast library prep and turnaround time.
A 58-gene pan-cancer panel with combined DNA content, utilizing the single-tube SLIMamp workflow for fast library prep and turnaround time.
Robust DNA NGS assay interrogating 48 genes across multiple solid tumor cancer types.
A robust next-generation sequencing (NGS) assay, based on the single-tube SLIMamp workflow, designed to interrogate genes relevant to both blood and solid organ cancers.
Reach out for information about our products and services, or get answers to questions about our technology.
